Tauopathies clinical trials
The registry lists 49 studies for Tauopathies across more than 10 countries. 13 are recruiting or about to start. Per ClinicalTrials.gov, last updated 2026-09-22.
Status
- Completed
- 23
- Recruiting
- 11
- Active, not recruiting
- 5
- Terminated
- 4
- Status unknown
- 2
- Not yet recruiting
- 1
Phase
- Phase 2
- 12
- Phase 1
- 11
- Early Phase 1
- 7
- Phase 3
- 2
Where
- United States
- 27
- France
- 6
- Canada
- 6
- Spain
- 5
- United Kingdom
- 5
- Taiwan
- 5
Who runs them
University of Pennsylvania (4) · University of California, San Francisco (4) · Inmune Bio, Inc. (3) · Chang Gung Memorial Hospital (3) · Eli Lilly and Company (3) · Tianjin Medical University (2) · Washington University School of Medicine (2) · MapLight Therapeutics (2)
Studies
Recruiting first, then most recently updated. Showing 49 of 49 — search for more.
- Tau PET/CT in Various Tau-Related Disease PatientsRecruitingNCT066909831 country
- [18F]NIDF PET Imaging in Tau-related DiseasesRecruitingNCT073065981 country
- Neurodegenerative Diseases Progression Markers (MARKERS-NDD)RecruitingNCT065967461 country
- A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease PsychosisRecruitingNCT06887192Phase 214 countries
- A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's DiseaseRecruitingNCT06297590Phase 13 countries
- An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease PsychosisEnrolling by invitationNCT07459660Phase 23 countries
- Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease - EUNot yet recruitingNCT07708675Not applicable
- F 18 T807 Tau PET Imaging of Alzheimer's DiseaseRecruitingNCT024143471 country
- Study of Biodistribution, Metabolism, Excretion and Brain Uptake11C-M503RecruitingNCT06303921Early Phase 11 country
- CW2IP2: Imaging and Diagnostic AssessmentsRecruitingNCT06083467Not applicable1 country
- Study of Biodistribution, Metabolism, Excretion and Brain Uptake 18F-JSS20-183ARecruitingNCT06932809Early Phase 11 country
- Study of Biodistribution, Metabolism, Excretion and Brain Uptake of 11C-HY-2-15RecruitingNCT06032026Early Phase 11 country
- The Influence of Vascular Burden, Amyloid Plaque and Tau Protein in Patients With Vascular Cognitive Impairment and Dementia With TauopathyRecruitingNCT04309253Phase 21 country
- A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)Active, not recruitingNCT05508789Phase 38 countries
- Study of Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of NIO752 in Early Alzheimer's Disease ParticipantsActive, not recruitingNCT05469360Phase 14 countries
- Head-to-Head Harmonization of Tau Tracers in Alzheimer's DiseaseActive, not recruitingNCT05361382Phase 13 countries
- First-in-Human Study for the Safety and Evaluation of Two 4R Tau Ligands as Potential PET Radioligands for Imaging Tau Protein in the BrainCompletedNCT07348276Early Phase 11 country
- A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of InflammationCompletedNCT05318976Phase 28 countries
- Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD SubjectsTerminatedNCT06304883Phase 33 countries
- A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's DiseaseCompletedNCT05063539Phase 25 countries
- Myotonic Dystrophy - Vascular and CognitionActive, not recruitingNCT046562101 country
- A Phase Ia/Ib, First-in-human (FIH) Study for Safety, Tolerability, Pharmacokinetics (PK), and Clinical Activity Evaluation of ADEL-Y01TerminatedNCT06247345Phase 11 country
- An Open-Label Extension of XPro1595 in Patients With Alzheimer's DiseaseTerminatedNCT05522387Phase 21 country
- Validation of Blood Biomarkers for Alzheimer's DiseaseCompletedNCT05427448Not applicable1 country
- 4-Repeat Tauopathy Neuroimaging Initiative - Cycle 2CompletedNCT029661452 countries
- A Study to Evaluate the Safety, Tolerability and Immunogenicity of Tau Targeted Vaccines in Participants With Early Alzheimer's DiseaseCompletedNCT04445831Phase 1/24 countries
- Pilot Pragmatic Clinical Trial to Embed Tele-Savvy Into Health Care SystemsCompletedNCT05080777Not applicable1 country
- Establishing 18F PMPBB3 (APN 1607) PET Imaging Markers for Diagnosis of Tauopathy Parkinsonism SyndromesCompletedNCT04557865Not applicable1 country
- CNS Tau Kinetics in Healthy Aging and Alzheimer's DiseaseCompletedNCT039388701 country
- Harmony at Home: A Pilot Telehealth Program for Rural ADRD CaregiversCompletedNCT05202223Not applicable1 country
- Study to Assess the Efficacy of XPro1595 in Patients With Mild Cognitive Impairment With Biomarkers of InflammationWithdrawnNCT05321498Phase 2
- A First-in-Human Study to Assess Single Doses of APNmAb005 in Healthy ParticipantsActive, not recruitingNCT05344989Phase 11 country
- A Bridging Study on Efficacy and Safety of [18F]Florbetaben PET for Diagnosis of Alzheimer Disease Subjects in Chinese PopulationCompletedNCT05527288Not applicable1 country
- Rho Kinase (ROCK) Inhibitor in Tauopathies - 1Status unknownNCT04734379Phase 21 country
- Human CNS Tau Kinetics in TauopathiesCompletedNCT035451261 country
- Novel Neuroimage Study in Tauopathies With ParkinsonismCompletedNCT03386669Phase 21 country
- A Double-Blind, Placebo-Controlled Safety and Efficacy Study of NA-831CompletedNCT03538522Phase 21 country
- Safety Study of TPI-287 to Treat CBS and PSPCompletedNCT02133846Phase 11 country
- BIIB092 in Primary Tauopathies: CBS, nfvPPA, sMAPT, and TESTerminatedNCT03658135Phase 11 country
- Tau PET Imaging With 18F-AV-1451 in Subjects With MAPT MutationsCompletedNCT02676843Phase 21 country
- 18F-PM-PBB3 PET Study in Tauopathy Including Alzheimer's Disease, Other Dementias and Normal ControlsCompletedNCT03625128Early Phase 11 country
- Expanded Access to ABBV-8E12No longer availableNCT03744546
- Davunetide (AL-108) in Predicted Tauopathies - Pilot StudyCompletedNCT01056965Phase 11 country
- A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of Intravenously Administered BMS-986168 in Healthy SubjectsCompletedNCT02294851Phase 11 country
- Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With TauopathiesCompletedNCT02531360Early Phase 11 country
- Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy SubjectsCompletedNCT02103894Phase 11 country
- COMPARATIVE EFFECTIVENESS OF MCI and DEMENTIA TREATMENTS IN A COMMUNITY-BASED DEMENTIA PRACTICECompletedNCT02860338
- 2-(1-{6-[(2-[F-18]Fluoroethyl) (Methyl)Amino]-2-naphthyl} Ethylidene) Malononitrile-PET for in Vivo Diagnose of Tauopathy in Unclassified ParkinsonismCompletedNCT02214862Early Phase 11 country
- The Long-Term Safety and Efficacy Follow-Up Study of Subjects Who Completed the Phase I Clinical Trial of Neurostem®-ADStatus unknownNCT016965911 country